Celularity partners with Fountain Life to offer cenplacel-L investigational cell therapy in Florida

Celularity Inc. Class A

Celularity Inc. Class A

CELU

0.00
  • Celularity partnered with Fountain Life to make its placental-derived investigational cell therapy cenplacel-L available for physician-directed use in Florida.
  • Rollout uses a new state framework effective July 1, 2025 that allows certain non-FDA-approved cell therapies under defined sourcing and consent safeguards.
  • Fountain Life will serve as an initial clinical channel, integrating diagnostics, patient selection, physician oversight, and longevity-focused care delivery.
  • Celularity will supply product from its FDA-registered, GMP-compliant facility, citing existing inventory to support near-term deployment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.